LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Search

Voyager Therapeutics Inc

Slēgts

3.49 0.29

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.4699999999999998

Max

3.5

Galvenie mērījumi

By Trading Economics

Ienākumi

-511K

-28M

Pārdošana

-13M

2.6M

EPS

-0.47

Peļņas marža

-1,077.401

Darbinieki

141

EBITDA

-455K

-29M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+357.14% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-31M

204M

Iepriekšējā atvēršanas cena

3.2

Iepriekšējā slēgšanas cena

3.49

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. jūn. 23:56 UTC

Mondelez International shares declined in after-market trading, continuing a trend of three consecutive lower closes amid rising US Treasury yields and mixed economic signals.

2026. g. 12. jūn. 23:56 UTC

ETF Constituents
Macro News

The U.S. government acquired a 10% stake in USA Rare Earth, boosting investor sentiment for gold-mining firms and contributing to GDX's after-market gains.

2026. g. 12. jūn. 23:51 UTC

Asia equity markets rise on U.S.-Iran peace deal optimism, while U.S. producer prices signal persistent inflation ahead of Fed's interest rate decision.

2026. g. 12. jūn. 23:51 UTC

Global equity markets rise on U.S.-Iran peace deal optimism, while U.S. consumer sentiment improves amid easing inflation concerns.

2026. g. 12. jūn. 23:51 UTC

European equity markets rise on optimism for U.S.-Iran peace deal, despite mixed economic data from the UK and easing inflation in Germany.

2026. g. 12. jūn. 23:51 UTC

US equity markets show mixed performance amid geopolitical developments and rising inflation concerns, with key economic indicators and Fed decisions on the horizon.

2026. g. 12. jūn. 23:51 UTC

U.S. Industrial Production MoM data set for June 15, 2026, forecasts a cautious optimism with a predicted increase of 0.2% following April's strong performance.

2026. g. 12. jūn. 23:51 UTC

United Airlines Holdings Inc. shares declined in after-market trading, despite initial gains, amid rising U.S. Treasury yields and mixed economic signals.

2026. g. 12. jūn. 23:46 UTC

Take-Two Interactive shares are higher in after-market trading, reflecting a modest gain since Friday's close, though still below the 20-day moving average.

2026. g. 12. jūn. 23:46 UTC

JD.Com Inc. shares are higher in after-market trading, despite no specific news. The stock is near the lower end of its one-month range.

2026. g. 12. jūn. 23:46 UTC

ETF Constituents

iShares MSCI South Korea ETF rises in after-hours trading, supported by top holding SKM. Global equity markets remain mixed amid geopolitical developments.

2026. g. 12. jūn. 23:41 UTC

Check Point Software Technologies shares are higher in after-market hours, with trading notably strong despite no specific news driving the movement.

2026. g. 12. jūn. 23:41 UTC

U.S. Retail Sales Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Geopolitical Tensions

2026. g. 12. jūn. 23:41 UTC

Cautious Optimism Surrounds Upcoming Canadian Housing Price Index Release Amidst Government Initiatives to Stabilize Market

2026. g. 12. jūn. 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Economic Uncertainties and Inflation Pressures

2026. g. 12. jūn. 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

2026. g. 12. jūn. 23:41 UTC

Fox Corp. shares are higher in after-market trading, reflecting a strong upward trajectory since Friday's close amid notable volatility.

2026. g. 12. jūn. 23:41 UTC

Baidu Inc. shares advanced in after-market trading, reaching a session high. The stock remains below its 20-day moving average amid rising bond yields.

2026. g. 12. jūn. 23:41 UTC

Correlated Moves

Bitcoin is trading lower on Friday, influenced by rising bond yields and a broader market decline in cryptocurrencies, including Ethereum.

2026. g. 12. jūn. 23:36 UTC

iShares Core U.S. Aggregate Bond ETF was roughly flat in after-market hours, maintaining stability near the upper end of its one-month trading range.

2026. g. 12. jūn. 23:36 UTC

Ross Stores Inc. shares declined in after-market trading, reflecting routine fluctuations. Broader market conditions were influenced by rising bond yields.

2026. g. 12. jūn. 23:36 UTC

The SPDR S&P Regional Banking ETF traded roughly flat in after-market hours, reflecting routine trading patterns amid mixed direction in broader U.S. stock indices.

2026. g. 12. jūn. 23:31 UTC

ETF Constituents
Macro News

Energy Select Sector SPDR Fund is lower in after-market hours, impacted by declines in Chevron and ExxonMobil, as broader market dynamics influence energy outlook.

2026. g. 12. jūn. 23:31 UTC

Market Awaits U.S. Building Permits Data Amid Mixed Sentiment and Economic Concerns Ahead of June 16 Release.

2026. g. 12. jūn. 23:31 UTC

Trip.com Group Ltd shares are higher in after-market trading, reaching a peak despite three consecutive lower daily finishes and being below its 20-day moving average.

2026. g. 12. jūn. 23:26 UTC

ETF Constituents
Macro News

The Industrial Select Sector SPDR Fund is trading higher in after-market hours, supported by positive industrial sector developments and gains among key holdings.

2026. g. 12. jūn. 23:26 UTC

ETF Constituents

The Materials Select Sector SPDR Fund is trading higher in after-market hours, supported by contributions from Freeport-McMoRan and Albemarle.

2026. g. 12. jūn. 23:22 UTC

Preliminary May 2026 Building Permits Data Set for Release Amid Cautious Optimism Following April's 5.8% Increase

2026. g. 12. jūn. 23:22 UTC

U.S. Export Prices Expected to Surge Amid Optimism from Geopolitical Developments and Recent Inflation Trends Ahead of June 16 Release

2026. g. 12. jūn. 23:22 UTC

Market Awaits May Housing Starts Data Amid Optimism for Real Estate Recovery and Government Initiatives on June 16, 2026.

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

357.14% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD  357.14%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

8

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
help-icon Live chat